MRI in female pelvis: an ESUR/ESR survey.
Stephanie Nougaret, Yulia Lakhman, Sophie Gourgou...
https://pubmed.ncbi.nlm.nih.gov/35347481Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID06144762
Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2025-02-12
150
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Pancreatic cancer presents a major health challenge with a low five-year survival rate of only 3% for most patients, partly due to late diagnosis and limited treatment options. This research aims to develop a model using multiscale radiomics to capture tumor heterogeneity by comparing images from in vivo MRI, ex vivo MRI, and histology. This approach seeks to improve early detection and personalized treatment monitoring for pancreatic cancer by providing a detailed, non-invasive tumor characterization. Participants will undergo collection of blood and tissue samples during surgery, including samples from the primary tumor and any metastases, as well as ex vivo MRI data. The imaging model developed will initially use these samples and MRI scans to create a virtual histology representation of the tumor. Eventually, this model will be applied to routine clinical MRI scans to aid in early cancer detection and treatment monitoring. Throughout the study, researchers will assess how well in vivo and ex vivo MRI combined with histology and molecular characteristics improve detection and monitoring of pancreatic cancer. Participants will be evaluated on the day of surgery with various imaging and molecular tests. The study involves analyzing tumor heterogeneity through advanced imaging and correlating MRI results with blood molecular biology data. The total participation duration varies, centering on the surgical timeframe and sample collection.
CONDITIONS
Brief Title
Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patient aged over 18 years
- Pathologically confirmed pancreatic cancer suitable for upfront or delayed surgery with neoadjuvant chemotherapy
- Negative pregnancy test for women who can become pregnant
- Affiliated with a social protection system
- Signed written informed consent before starting the project
You will not qualify if you...
- Presence of metastases
- Patient not scheduled for surgery
- Pregnant or breastfeeding women
- Mental, psychological, physical, or legal incapacity preventing participation in the project
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - Day of the surgery
Participants undergo surgery during which tissue and blood samples are collected for imaging and molecular analysis.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
NOUGARET Stephanie
Montpellier, France, 34298
Actively Recruiting
Loading map...
Research Team
M
MOUSSION Aurore
T
Texier Emmanuelle
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Gender diversity in authorship in Diagnostic & Interventional Imaging: Where are we now?
Philippe Soyer, Marie-Pierre Revel, Anthony Dohan...
https://pubmed.ncbi.nlm.nih.gov/35183485Assessing Histology Structures by Ex Vivo MR Microscopy and Exploring the Link Between MRM-Derived Radiomic Features and Histopathology in Ovarian Cancer.
Marion Tardieu, Yulia Lakhman, Lakhdar Khellaf...
https://pubmed.ncbi.nlm.nih.gov/35127479O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.
Elizabeth A Sadowski, Isabelle Thomassin-Naggara, Andrea Rockall...
https://pubmed.ncbi.nlm.nih.gov/35040672Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group.
Atul B Shinagare, Elizabeth A Sadowski, Hyesun Park...
https://pubmed.ncbi.nlm.nih.gov/34846566Radiomics modelling in rectal cancer to predict disease-free survival: evaluation of different approaches.
H Tibermacine, P Rouanet, M Sbarra...
https://pubmed.ncbi.nlm.nih.gov/34423347BJR female genitourinary oncology special feature: introductory editorial.
Stephanie Nougaret, Hebert Alberto Vargas, Evis Sala
https://pubmed.ncbi.nlm.nih.gov/34415200Tailored Strategy for Locally Advanced Rectal Carcinoma (GRECCAR 4): Long-term Results From a Multicenter, Randomized, Open-Label, Phase II Trial.
Philippe Rouanet, Eric Rullier, Bernard Lelong...
https://pubmed.ncbi.nlm.nih.gov/34759247Radiomics: an Introductory Guide to What It May Foretell.
Stephanie Nougaret, Hichem Tibermacine, Marion Tardieu...
https://pubmed.ncbi.nlm.nih.gov/31240403Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer.
Britta Weigelt, Hebert Alberto Vargas, Pier Selenica...
https://pubmed.ncbi.nlm.nih.gov/32914032